OTLK
insider transactionsOutlook Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 5 different insiders made open-market purchases in the last 365 days, totalling $5.3M.
Net shares · 365d
+21.2M
21.2M buy · 0 sell
Net value · 365d
$5.3M
$5.3M in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
8
21.2M buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Director
$24.1K
29.0K sh · $0.83
Own +78%
-
Buy·P
Ghiath M. Sukhtian / GMS Ventures & Investments
Director, 10% Owner
—
8.6M sh
Own New
-
Other·H
Ghiath M. Sukhtian / GMS Ventures & Investments
Director, 10% Owner
—
8.6M sh
-
Buy·P
Ghiath M. Sukhtian / GMS Ventures & Investments
Director, 10% Owner
—
3.5M sh
Own New
-
Other·H
Ghiath M. Sukhtian / GMS Ventures & Investments
Director, 10% Owner
—
3.5M sh
-
Buy·P
Ghiath M. Sukhtian / GMS Ventures & Investments
Director, 10% Owner
$5.0M
8.5M sh · $0.59
Own +63%
-
Buy·P
Director
$50.0K
122.2K sh · $0.41
Own +3593%
-
Buy·P
Director
$2.1K
5.0K sh · $0.43
Own +843%
-
Buy·P
Director
$15.0K
34.0K sh · $0.44
Own +1074%
-
Buy·P
Director
$176.5K
400.0K sh · $0.44
Own +1691%
-
Grant·A
Director
$91.5K
536 sh · $170.66
Own +3%
-
Grant·A
Director
$0
766 sh
Own +3%
-
Grant·A
Director
$92.4K
357 sh · $258.87
Own +2%
-
Grant·A
Director
$158.2K
611 sh · $258.87
Own +22%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2026 | Yezan Munther Haddadin | Buy P | 29.0K | $24.1K |
| May 28, 2026 | Ghiath M. Sukhtian / GMS Ventures & Investments | Buy P | 8.6M | — |
| May 28, 2026 | Ghiath M. Sukhtian / GMS Ventures & Investments | Other H | 8.6M | — |
| May 28, 2026 | Ghiath M. Sukhtian / GMS Ventures & Investments | Buy P | 3.5M | — |
| May 28, 2026 | Ghiath M. Sukhtian / GMS Ventures & Investments | Other H | 3.5M | — |
| May 28, 2026 | Ghiath M. Sukhtian / GMS Ventures & Investments | Buy P | 8.5M | $5.0M |
| May 27, 2026 | Faisal Ghiath Sukhtian | Buy P | 122.2K | $50.0K |
| May 26, 2026 | Randy H Thurman | Buy P | 5.0K | $2.1K |
| May 26, 2026 | Yezan Munther Haddadin | Buy P | 34.0K | $15.0K |
| May 26, 2026 | Kurt J Hilzinger | Buy P | 400.0K | $176.5K |
| Mar 31, 2026 | Kurt J Hilzinger | Grant A | 536 | $91.5K |
| Jan 2, 2026 | Kurt J Hilzinger | Grant A | 766 | $0 |
| Dec 31, 2025 | Kurt J Hilzinger | Grant A | 357 | $92.4K |
| Dec 31, 2025 | Kurt J Hilzinger | Grant A | 611 | $158.2K |
About OTLK insider trading
This page tracks insider transactions for Outlook Therapeutics, Inc. (OTLK) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.